» Authors » Christina Ganster

Christina Ganster

Explore the profile of Christina Ganster including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 685
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzeo P, Ganster C, Wiedenhoft J, Shirneshan K, Rittscher K, Brzuszkiewicz E, et al.
Hemasphere . 2024 Sep; 8(9):e70014. PMID: 39315323
The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important...
2.
Crisa E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymaki M, et al.
Leukemia . 2024 Aug; 38(10):2259-2265. PMID: 39103678
Lenalidomide (LEN) can induce red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) myelodysplastic neoplasm (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression,...
3.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H, et al.
Blood . 2024 Jul; 144(15):1617-1632. PMID: 38958467
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current...
4.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa J, et al.
Blood . 2024 Apr; 144(11):1221-1229. PMID: 38687605
Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence...
5.
Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y, et al.
NEJM Evid . 2024 Feb; 1(7):EVIDoa2200008. PMID: 38319256
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are...
6.
Sockel K, Gotze K, Ganster C, Bill M, Georgi J, Balaian E, et al.
Ann Hematol . 2024 Jan; 103(3):993-997. PMID: 38214707
The VEXAS syndrome, a genetically defined autoimmune disease, associated with various hematological neoplasms has been attracting growing attention since its initial description in 2020. While various therapeutic strategies have been...
7.
Treiber H, Ganster C, Schanz J, Shimono J, Zechel S, Pohanyar N, et al.
Ann Hematol . 2023 Sep; 102(12):3631-3633. PMID: 37702823
No abstract available.
8.
Mallo M, Tuechler H, Arenillas L, Raynaud S, Cluzeau T, Shih L, et al.
EJHaem . 2023 May; 4(2):446-449. PMID: 37206269
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of...
9.
Eder L, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al.
Curr Oncol . 2023 Jan; 30(1):1146-1150. PMID: 36661736
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing...
10.
Braulke F, Schweighofer A, Schanz J, Shirneshan K, Ganster C, Pollock-Kopp B, et al.
Leuk Res . 2022 Dec; 124:106996. PMID: 36538857
In this single center retrospective analysis 76 patients with high-risk (HR) myelodysplastic syndrome (MDS) treated with azacitidine (AZA) were reviewed for response, especially cytogenetic response (cyR) using repeated chromosome banding...